And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. Like many others, we will take time to observe ancient traditions, one of which includes welcoming the stranger, a gesture that, unfortunately, seems to be lost on some folks these days. Otherwise, we hope to catch up on our reading and hang with all of our short people, a rare occurrence. And what about you? This is a fine time to enjoy the great outdoors — exercise is a good thing — or make time for someone special. Or perhaps you might simply want to reflect on the state of events, such as they are. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

A lower dose of non-opioid painkiller developed by Pfizer (PFE) and Eli Lilly (LLY) failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, Reuters writes. The drug, called tanezumab, belongs to a new category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and has been touted as a potential blockbuster. The study tested two doses and the higher dose of the treatment met two of the three main goals, in which it reduced pain and improved physical function.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy